Compare NRT & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRT | EQ |
|---|---|---|
| Founded | 1975 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.0M | 89.4M |
| IPO Year | 1995 | 2018 |
| Metric | NRT | EQ |
|---|---|---|
| Price | $6.95 | $1.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.56 |
| AVG Volume (30 Days) | 20.5K | ★ 439.5K |
| Earning Date | 09-08-2026 | 11-12-2026 |
| Dividend Yield | ★ 9.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.52 | $1.16 |
| 52 Week High | $10.49 | $6.20 |
| Indicator | NRT | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 22.01 | 44.12 |
| Support Level | $6.87 | $1.30 |
| Resistance Level | $8.74 | $1.51 |
| Average True Range (ATR) | 0.34 | 0.13 |
| MACD | -0.10 | 0.04 |
| Stochastic Oscillator | 15.88 | 62.86 |
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.